Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Artiva Biotherapeutics, Inc. |
|---|---|
| Ticker | ARTV |
| CIK | 0001817241 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 211,6 Mio. USD |
| Beta | 1,48 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -83,865,000 | -3.43 | 130,940,000 | 109,970,000 |
| 2025-09-30 | 10-Q | -21,528,000 | -0.88 | 148,862,000 | 129,224,000 | |
| 2025-06-30 | 10-Q | -21,254,000 | -0.87 | 169,391,000 | 149,041,000 | |
| 2025-03-31 | 10-Q | -20,311,000 | -0.83 | 191,263,000 | 168,783,000 | |
| 2024-12-31 | 10-K | 251,000 | -65,373,000 | -5.81 | 209,581,000 | 186,641,000 |
| 2024-09-30 | 10-Q | 251,000 | -17,472,000 | -0.92 | 225,596,000 | 200,996,000 |
| 2024-06-30 | 10-Q | 251,000 | -17,843,000 | -22.00 | 75,912,000 | -191,097,000 |
| 2024-03-31 | 10-Q | 251,000 | -13,963,000 | -17.24 | -174,673,000 | |
| 2023-12-31 | 10-K | 33,492,000 | -28,720,000 | -35.78 | 105,114,000 | -162,015,000 |
| 2023-09-30 | 10-Q | 26,656,000 | 11,279,000 | 1.62 | -151,454,000 | |
| 2023-06-30 | 10-Q | 3,497,000 | -11,284,000 | -14.09 | -164,255,000 | |
| 2023-03-31 | 10-Q | -16,717,000 | -155,574,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | Aslan Fred | Director, Officer, President and CEO | Open Market Sale | -25,500 | 6.00 | -153,000.00 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.